XML 73 R56.htm IDEA: XBRL DOCUMENT
v3.23.1

Research and development expenses (Details) - USD ($) $ in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Research and development expenses |  |  |
Pre-clinical and clinical trial expenses | $ 28,178 | $ 14,188 | $ 11,325
Personnel-related expenses | 6,150 | 4,955 | 2,276
Research and development activities expenses | 2,241 | 1,843 | 1,022
Share-based compensation expense | 1,975 | 788 | 232
Facilities and other research and development expenses | 1,546 | 814 | 643
VUmc and other license expenses | 15 | 14,357 | 203
Total research and development expenses | 40,105 | 36,945 | 15,701
Government grants | $ 1,600 | $ 1,700 | $ 1,000

X
- Definition The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 55 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_GovernmentGrants
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of expenditure directly attributable to research or development activities, recognised in profit or loss. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2022-03-24 -Paragraph 126 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_ResearchAndDevelopmentExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of facilities and other research and development expenses directly attributable to research or development activities, recognised in profit or loss. + References No definition available. + Details
Name: | lvtx_ResearchAndDevelopmentExpenseFacilitiesAndOtherExpenses
Namespace Prefix: | lvtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of personnel-related expenses directly attributable to research or development activities, recognised in profit or loss. + References No definition available. + Details
Name: | lvtx_ResearchAndDevelopmentExpensePersonnelRelatedExpenses
Namespace Prefix: | lvtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of pre-clinical and clinical trial expenses directly attributable to research or development activities, recognised in profit or loss. + References No definition available. + Details
Name: | lvtx_ResearchAndDevelopmentExpensePreClinicalAndClinicalTrialExpenses
Namespace Prefix: | lvtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of research and development activities expenses directly attributable to research or development activities, recognised in profit or loss. + References No definition available. + Details
Name: | lvtx_ResearchAndDevelopmentExpenseResearchAndDevelopmentActivitiesExpenses
Namespace Prefix: | lvtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of share-based compensation expense directly attributable to research or development activities, recognised in profit or loss. + References No definition available. + Details
Name: | lvtx_ResearchAndDevelopmentExpenseShareBasedCompensationExpense
Namespace Prefix: | lvtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | lvtx_ResearchAndDevelopmentExpensesAbstract
Namespace Prefix: | lvtx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of license expenses directly attributable to research or development activities, recognised in profit or loss. + References No definition available. + Details
Name: | lvtx_ResearchAndDevelopmentLicenseExpenses
Namespace Prefix: | lvtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration